開発中の造影剤腎症治療薬市場2022年:ステージ、ターゲット、MoA、RoA、分子タイプ、キープレーヤー

■ 英語タイトル:Contrast Induced Nephropathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

調査会社Global Markets Direct社が発行したリサーチレポート(データ管理コード:GMDHC22090IDB)■ 発行会社/調査会社:Global Markets Direct
■ 商品コード:GMDHC22090IDB
■ 発行日:2022年3月
■ 調査対象地域:グローバル
■ 産業分野:医薬品
■ ページ数:32
■ レポート言語:英語
■ レポート形式:PDF
■ 納品方式:Eメール
■ 販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,000 ⇒換算¥296,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥592,000見積依頼/購入/質問フォーム
Enterprisewide Price(複数事業所内共有可)USD6,000 ⇒換算¥888,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行・送付致します。(請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能)
Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[開発中の造影剤腎症治療薬市場2022年:ステージ、ターゲット、MoA、RoA、分子タイプ、キープレーヤー]についてメールでお問い合わせはこちら
*** レポート概要(サマリー)***

本調査レポートでは、開発中の造影剤腎症治療薬市場について調査・分析し、造影剤腎症概要、治療薬開発、パイプライン概要、企業別のパイプライン、企業別の開発中製品、治療薬分析、標的別分析、作用機序別分析、投与経路別分析、分子タイプ別分析、治療薬開発に携わる企業など、以下の項目を掲載しております。
・造影剤腎症-概要
・造影剤腎症-治療薬開発
・パイプライン概要
・企業別のパイプライン
・企業別の開発中製品
・造影剤腎症-治療薬分析
・標的別分析
・作用機序別分析
・投与経路別分析
・分子タイプ別分析
・造影剤腎症-治療薬開発に携わる企業

Contrast Induced Nephropathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Contrast Induced Nephropathy – Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Contrast Induced Nephropathy (Genito Urinary System And Sex Hormones) pipeline landscape.

Contrast-induced nephropathy (CIN) is defined as the impairment of renal function (measured as either a 25%increase in serum creatinine (SCr) from baseline or a 0.5 mg/dL (44 μmol/L) increase in absolute SCr value after 48-72 hrs contrast administration). Symptoms include feeling more tired, poor appetite, swelling in the feet and ankles,puffiness around the eyes, or dry and itchy skin. Risk factors include age, diabetes, decreased kidney function and congestive heart failure. Treatment includes electrolyte management.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Contrast Induced Nephropathy – Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Contrast Induced Nephropathy (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Contrast Induced Nephropathy (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Contrast Induced Nephropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 3, 3 and 1 respectively.

Contrast Induced Nephropathy (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Contrast Induced Nephropathy (Genito Urinary System And Sex Hormones).
- The pipeline guide reviews pipeline therapeutics for Contrast Induced Nephropathy (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Contrast Induced Nephropathy (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Contrast Induced Nephropathy (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Contrast Induced Nephropathy (Genito Urinary System And Sex Hormones)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Contrast Induced Nephropathy (Genito Urinary System And Sex Hormones).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Contrast Induced Nephropathy (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

*** レポート目次(コンテンツ)***

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Contrast Induced Nephropathy – Overview
Contrast Induced Nephropathy – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Contrast Induced Nephropathy – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Contrast Induced Nephropathy – Companies Involved in Therapeutics Development
Daiichi Sankyo Co Ltd
Pharming Group NV
Radikal Therapeutics Inc
Saghmos Therapeutics Inc
Contrast Induced Nephropathy – Drug Profiles
carperitide – Drug Profile
Product Description
Mechanism Of Action
conestat alfa – Drug Profile
Product Description
Mechanism Of Action
History of Events
R-100 – Drug Profile
Product Description
Mechanism Of Action
History of Events
R-801 – Drug Profile
Product Description
Mechanism Of Action
History of Events
R-901 – Drug Profile
Product Description
Mechanism Of Action
History of Events
R-911 – Drug Profile
Product Description
Mechanism Of Action
History of Events
trimetazidine – Drug Profile
Product Description
Mechanism Of Action
Contrast Induced Nephropathy – Dormant Projects
Contrast Induced Nephropathy – Discontinued Products
Contrast Induced Nephropathy – Product Development Milestones
Featured News & Press Releases
Oct 17, 2018: Pharming reports positive data from first investigator-initiated study of rhC1-Inhibitor (RUCONEST) in Contrast-induced Nephropathy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Contrast Induced Nephropathy, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Contrast Induced Nephropathy - Pipeline by Daiichi Sankyo Co Ltd, 2022
Contrast Induced Nephropathy - Pipeline by Pharming Group NV, 2022
Contrast Induced Nephropathy - Pipeline by Radikal Therapeutics Inc, 2022
Contrast Induced Nephropathy - Pipeline by Saghmos Therapeutics Inc, 2022
Contrast Induced Nephropathy - Dormant Projects, 2022
Contrast Induced Nephropathy - Discontinued Products, 2022

List of Figures
Number of Products under Development for Contrast Induced Nephropathy, 2022
Number of Products under Development by Companies, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/



※注目の調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(GMDHC22090IDB )"開発中の造影剤腎症治療薬市場2022年:ステージ、ターゲット、MoA、RoA、分子タイプ、キープレーヤー" (英文:Contrast Induced Nephropathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update)はGlobal Markets Direct社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。